GoodRx posted second-quarter 2026 revenue of $200.4 million, down 1% year over year; GAAP net income fell 34% to $8.5 million.
GAAP net margin narrowed 2 percentage points to 4.3%; non-GAAP adjusted EBITDA slipped 8% to $63.7 million, with margin down 2.4 points to 31.8%.
Subscription revenue climbed 39% to $28.5 million; Pharma Direct revenue rose 76% to $61.6 million.
Prescription transactions revenue dropped 26% to $106.4 million, on lower Monthly Active Consumers tied to retail pharmacy shifts and reduced volume at an integrated savings program.
GoodRx raised full-year 2026 guidance to revenue of $790 million-$805 million; projected non-GAAP adjusted EBITDA of $240 million-$250 million.
GDRX•
